Literature DB >> 25085953

Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.

Waka Yokoyama1, Kazuki Takada1, Nobuyuki Miyasaka1, Hitoshi Kohsaka1.   

Abstract

A 64-year-old woman presented with an acute onset of myelitis and optic neuritis after 47 months of etanercept use for rheumatoid arthritis. Etanercept was discontinued and pulse methylprednisolone therapy (1000 mg/day for 3 days) was started, followed by a quick and complete resolution. Demyelination associated with antitumor necrosis factor agents, reported to develop mostly from 1 week to 12 months after the initiation of the agents, could develop after a few years and thus warrants vigilant monitoring. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25085953      PMCID： PMC4127673          DOI： 10.1136/bcr-2014-205779

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  23 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

Review 2.  Central nervous system disease in Sjögren's syndrome. New insights into immunopathogenesis.

Authors:  E Alexander
Journal:  Rheum Dis Clin North Am       Date:  1992-08       Impact factor: 2.670

3.  New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.

Authors:  Makoto Tanno; Ichiro Nakamura; Shunsuke Kobayashi; Kumiko Kurihara; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2006-11       Impact factor: 2.980

4.  The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.

Authors:  M S Heiberg; C Kaufmann; E Rødevand; K Mikkelsen; W Koldingsnes; P Mowinckel; T K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

Review 5.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 8.  Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Authors:  Hyon J Kwon; Timothy R Coté; Michael S Cuffe; Judith M Kramer; M Miles Braun
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391

9.  Sjögren syndrome: central nervous system manifestations.

Authors:  G E Alexander; T T Provost; M B Stevens; E L Alexander
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

10.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889
View more
  6 in total

1.  Iatrogenic transverse myelitis in a patient with rheumatoid arthritis.

Authors:  Pournamy Sarathchandran; Ayman Alboudi; Reem AlSuwaidi; Abubaker AbdulRahman Almadani
Journal:  BMJ Case Rep       Date:  2019-03-20

2.  An Overview of The Role of Tumor Necrosis Factor-Alpha in Epileptogenesis and Its Terapeutic Implications.

Authors:  Alexandre Michev; Alessandro Orsini; Viola Santi; Francesco Bassanese; Daniele Veraldi; Ilaria Brambilla; Gian Luigi Marseglia; Salvatore Savasta; Thomas Foiadelli
Journal:  Acta Biomed       Date:  2022-03-21

3.  Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.

Authors:  Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

Review 4.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

5.  A diffusion-based quantification technique for assessment of sacroiliitis in adolescents with enthesitis-related arthritis.

Authors:  Kanimozhi Vendhan; Timothy J P Bray; David Atkinson; Shonit Punwani; Corinne Fisher; Debajit Sen; Yiannakis Ioannou; Margaret A Hall-Craggs
Journal:  Br J Radiol       Date:  2015-12-07       Impact factor: 3.039

Review 6.  A review of ocular adverse events of biological anti-TNF drugs.

Authors:  Fernanda Nicolela Susanna; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.